Abbvie Inc ABBV

$286.01 -6.81 (-2.33%)

Valuation

Market cap
520,651,264,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
23.00
P/E (forward)
21.10
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
4,839,200
Avg volume
4,934,646
Day's range
$284.91 – $292.55
Shares out
1,767,616,000
Stochastic %K
54%
Beta
0.20
Analysts
Moderate Buy
Price target
$311.30

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

Bobear12 Nov 18, 10:32 PM
$ABBV ! could MDGL troubling news start to create interest in GALT? What are the chances for fast track approval from the FDA?
0 replies
Bobear12 Nov 18, 10:18 PM
$ABBV hello thought you should know. Galectin Therapeutics Inc. (GALT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy).
0 replies
JoinTheDiscussionGroup14 Nov 18, 8:40 PM
💊 Pharmaceutical Innovation: The Pipeline Matters Drugmakers depend on research, successful clinical trials, and the ability to commercialize new treatments. $ABBV has exposure to immunology and neuroscience, while $REGN focuses on innovative biotechnology medicines. $MRK (Merck) has a broad pharmaceutical and vaccine portfolio. Clinical results, patent protection, and product launches will shape future growth.
0 replies
JoinTheDiscussionGroup67 Nov 18, 7:20 PM
💊 Pharmaceutical Stocks: Innovation and Patent Strategy Matter Large pharmaceutical companies depend on drug development, commercial execution, and successful product pipelines. $ABBV (AbbVie) has exposure to immunology and neuroscience treatments, while $REGN (Regeneron) focuses on biotechnology and innovative medicines. $PFE (Pfizer) continues developing its pharmaceutical and vaccine portfolio. Clinical results, patent expirations, new product launches, and revenue guidance are important factors.
0 replies
SparkyReturns Nov 18, 5:34 PM
$ICU This will be a change in paradigm for so many indications and companies with related drugs and support for these condition. $JNJ $ABBV $MRK $LLY
0 replies
KryptonResearch14 Nov 18, 5:15 PM
My favorite Abstraction piece to work on yet! Biotech is set for a massive revolution as AI accelerates how we cure disease and it’s arguably the greatest AI application of them all. $XBI $LABU $JNJ $PFE $ABBV This month we look at this new paradigm and its investment ramifications. As always, abstractions are free to read: https://kryptonresearch.substack.com/p/volume-iii-in-search-of-a-cure
0 replies
middleman Nov 18, 3:59 PM
$ABBV we have been gettin beat up a little
0 replies
AdamBrennan2 Nov 18, 11:22 AM
c4 therapeutics $CCCC is a biotech building drugs that destroy disease-causing proteins instead of just blocking them, and it has no product on the market yet but look at who is around it: merck kgaa, roche, pfizer and betta pharma are all partners or suppliers in the picture big names are already working with a company that has no sales to me this looks more like a lab with serious partners than a lonely bet, though the drugs still have to work $ABBV $AMGN $GILD $VRTX
1 replies